×
BFRG dropped -7.55%, falling from Friday's $0.53 close to $0.49 during Monday's regular session. The decline extends selling pressure from Friday's Q3 2026 release, where revenue of $63,578 landed roughly -70% below the ~$215,000 consensus and -24% year over year, while EPS of -$0.11 missed the -$0.09 estimate and the operating loss widened to $2.05 million.
CareCloud's recurring, technology-enabled revenue now represents roughly 75% of sales, a structural shift that supports a more predictable medium-term revenue base and margin profile. Management has reaffirmed full-year 2026 guidance for revenue of $128 million to $132 million, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $29 million to $31 million, and GAAP earnings per share of $0.20 to $0.23.
The central target of $6.00 is the rounded arithmetic mean of the verified analyst price targets reviewed, which span a wide range from $2.50 to $8.00. At a recent price near $2.42, reaching $6.00 would require upside of roughly 148%, a very large move relative to the stock's current level.
CareCloud (CCLD) shares climbed roughly 36.7% over the last 30 days, rising from a closing price of $1.77 on October 14, 2026, to $2.42 on November 13, 2026. The advance was fueled by record third-quarter 2026 results reported on November 5, 2026, including record GAAP net income, record GAAP EPS, and record adjusted EBITDA.
Zhongchao Inc. (ZCMD) shares declined roughly 34% over the last 30 days, sliding from about $1.38 to near $0.90. The pullback pushed the stock back below the $1.00 Nasdaq minimum bid price threshold, renewing listing-compliance concerns.
HTFL dropped from the prior close of $59.92 to $52.09, a -13.07% decline, with the move taking place during Friday's regular session after shares opened sharply lower. The sell-off followed a third-quarter beat-and-raise that left little room for error: revenue rose +57.4% to $72.9 million and non-GAAP EPS of -$0.03 topped the -$0.10 consensus, yet the raised $262–$264 million full-year guide implies Q4 revenue roughly flat versus Q3, ending three straight quarters of acceleration after the stock had already run +51% into the print.
OptimizeRx (OPRX) fell -5.41% to $8.39 from the prior close of $8.87, with selling starting premarket near $8.50 and extending into Friday's regular session. No verified news or fundamental catalyst found for today's drop; it is likely profit-taking after Thursday's sharp +40% rebound off a $6.33 low, consistent with a micro-cap that averages roughly a 2.4% daily swing.
The central $4.00 target is the arithmetic mean of four identifiable analyst price targets — $2.00 from Maxim Group, $4.00 from B. Riley Securities, and $5.00 each from StoneX and Benchmark — across a wide $2.00-to-$5.00 range. At the latest price near $0.41, reaching $4.00 requires roughly 875% upside, a very large move by any standard.
HeartBeam reported a third-quarter net loss of $3.0 million, or $0.05 per share, versus a loss of $5.3 million, or $0.15 per share, a year earlier. The result beat the consensus estimate of a $0.09 per-share loss, though revenue remained effectively zero against a roughly $76,500 forecast.
The $9 central target is the arithmetic mean of four verified, current analyst price targets, which span roughly $6 to $12. With the latest price near $1.65, reaching $9 would require upside of about 445% — an exceptionally large move for a micro-cap stock.
Third quarter 2026 revenue rose 6% year over year to $5.3 million, marking a return to growth after a decline in the prior quarter. Net loss narrowed to $8.8 million from $10.5 million a year earlier, though the per-share loss came in modestly wider than consensus.
The central $70 target is not an analyst consensus ; it is a round-number technical and psychological objective drawn from public discussion of the stock's breakout above its 52-week high. The latest verified price is roughly $59–$60, meaning a move to $70 would require approximately 17%–18% upside — a substantial move, not a marginal one.
HeartFlow reported third-quarter 2026 revenue of $72.9 million, up 57.4% year over year and well above the consensus estimate of $65.2 million. Non-GAAP (adjusted) earnings per share came in at a loss of $0.03, beating consensus expectations of a $0.10 loss by $0.07.
CLARITY trial progress is the pivotal catalyst: Aclarion's prospective, randomized 300-patient study of its Nociscan platform now spans eleven clinical sites, with management expecting to update enrollment progress and initial readout timing by year-end 2026. Reimbursement momentum is broadening: Nociscan is already reimbursed by three of the four largest private U.K. insurers (Vitality, AXA, and Aviva), while a newly launched U.S. Market Access Program with PRIA Healthcare targets domestic payer coverage.
Aclarion, Inc. is a commercial-stage healthcare technology company that uses Magnetic Resonance Spectroscopy (MRS) and proprietary AI algorithms to help physicians locate the source of chronic low back pain. The company's flagship product is Nociscan , a cloud-based software-as-a-service (SaaS) platform that analyzes MRI spectroscopy data to indicate whether a spinal disc may be causing pain.
AI-driven recurring revenue is the central growth engine. The Dynamic Audience Activation Platform (DAAP), which uses machine learning to target healthcare professionals and patients, is scaling rapidly and is expected to anchor the shift toward more predictable subscription revenue. A shift toward subscriptions should improve revenue visibility. Management continues to emphasize subscription-based contracts, which could reduce quarterly variability and support a steadier future outlook even as top-line growth faces near-term pressure.
OPRX is the Nasdaq-listed stock of OptimizeRx Corporation, a digital healthcare technology company serving the life sciences industry. The company helps pharmaceutical and life sciences brands connect with healthcare professionals (HCPs) and patients at key treatment decision points.
Tempus AI (TEM) fell from a prior close of $79.43 to $74.64, a decline of -6.03%, during regular trading hours. No verified news or fundamental catalyst found; the drop is consistent with profit-taking after a sharp run, as shares climbed from roughly $64 in early October to about $84 on November 9 before fading.
OneMedNet (ONMD) slipped -0.37% to $5.35 from a $5.37 prior close, trading essentially flat during regular market hours. No verified news or fundamental catalyst found — the tiny move is consistent with quiet, normal trading in a micro-cap whose typical daily swing is roughly +/−5%, rather than any single development.
TEM shares dropped -7.08% during regular trading hours, sliding from a previous close of $79.43 to $73.81. No verified news or fundamental catalyst found. The decline is consistent with profit-taking in a stock that has roughly doubled since late July and posted moves of 7% or more on 16 of its last 63 sessions.